RoosterBio

Founded in 2015 and headquartered in Frederick, Maryland, RoosterBio is a private company operating as a critical enabler in the cell therapy, gene therapy, and regenerative medicine sectors. It functions on a platform and product business model, supplying standardized, high-quality hMSCs and associated bioprocessing tools to over 500 academic, institutional, and industry partners globally. By offering industrialized raw materials with built-in protocols, RoosterBio aims to de-risk and accelerate its customers' therapeutic development programs, supporting them from research through tech transfer and commercial-scale manufacturing.

Standardized, scalable bioprocessing systems for human mesenchymal stem/stromal cells (hMSCs) and exosomes. The platform integrates high-volume, characterized hMSCs, highly productive bioprocess media, and detailed protocols for 2D and 3D expansion, designed to deliver the lowest cost per million cells and enable industrialized therapeutic manufacturing.

RoosterBio competes with large, diversified life science tools companies (e.g., Thermo Fisher Scientific, Lonza) that offer MSC and media products, as well as smaller specialized biotech suppliers. Its key differentiators are its focused, integrated systems approach, emphasis on scalability and low cost-of-goods, and strong regulatory support. It is often cited as a 'gold standard' for MSC manufacturing within the industry.